目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T7882 | Others COX Autophagy | ||
Indomethacin farnesil (Infree) 是具有口服活性的 Indomethacin 前药,可通过干扰溶酶体的正常功能来破坏自噬流,有抗炎和抗风湿作用。它是一种可透过血脑屏障的,非选择性的 COX1和 COX2抑制剂,在 CHO 细胞中,对人 COX-1 和 COX-2 的IC50值分别为 18 nM 和 26 nM。 | |||
T7113 | COX | ||
Paradol ([6]-Gingerone) 是一种姜科植物中发现的酚类天然产物,具有抗癌、抗炎、抗氧化和神经保护作用。在小鼠皮肤癌变中,可结合到环氧合酶(COX-2) 活性位点。 | |||
T6387 | COX | ||
Ampiroxicam (Flucam) 是一种非选择性的环氧化酶抑制剂,有抗炎活性。 | |||
T3399 | Others Estrogen/progestogen Receptor Reactive Oxygen Species Lipoxygenase Gamma-secretase Akt COX Antibacterial | ||
Psoralidin 是COX-2和5-LOX 的抑制剂,有抗癌,抗菌和抗炎作用。它显著下调NOTCH1信号传导,还极大地诱导活化氧产生。 | |||
T0291 | Apoptosis COX MRP | ||
Flurbiprofen (dl-Flurbiprofen) 是一种高效的,具有口服活性的非甾体抗炎化合物,有退热止痛活性, 常用于炎症性疾病的研究。它是一种非选择性的环氧合酶抑制剂,可研究结肠癌。 | |||
T0219 | COX | ||
Valdecoxib (SC 65872) 是可口服的高选择性 COX-2抑制剂,对 COX-2 和 COX-1 的 IC50值分别为 5 nM 和 140 μM,可用于治疗骨关节炎、类风湿性关节炎以及痛经和经期症状。 | |||
T3342 | Apoptosis Others Influenza Virus COX Acyltransferase HSV | ||
Xanthohumol 是从啤酒花中分离到的黄酮类化合物,可抑制 COX-1 和 COX-2 活性,具有抗肿瘤,抗血管生成的作用,还具有抗多种病毒的活性。 | |||
T0649 | Apoptosis Mitophagy COX Endogenous Metabolite Autophagy | ||
Salicylic acid (2-Hydroxybenzoic acid) 是一种从柳树皮中提取的天然产物,是一种抗炎活性环加氧酶抑制剂,抑制COX-2活性。 | |||
T2778 | Antioxidant COX | ||
(+)-Catechin hydrate 是来自茶树的抗氧化类黄酮,可抑制环加氧酶-1,IC50为 1.4 μM。它是一种自由基清除剂,可防止多种生物系统中自由基介导的损害。 | |||
T5460 | COX | ||
Mofezolac 是一种非甾体类抗炎药,可缓解疼痛并具有抗炎活性,抑制 COX-1和COX-2的IC50为 1.44 和 447 nM。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-01736 | COX-2 Protein, Human, Recombinant (His) | Human | Baculovirus Insect Cells | ||
PTGS2, also known as COX-2, is s component of Prostaglandin-endoperoxide synthase (PTGS). PTGS, also known as cyclooxygenase, is the key enzyme in prostaglandin biosynthesis, and acts both as a dioxygenase and as a peroxidase. There are two isozymes of PTGS: a constitutive PTGS1 and an inducible PTGS2, which differ in their regulation of expression and tissue distribution. PTGS2 is overexpressed in many cancers. The overexpression of PTGS2 along with increased angiogenesis and GLUT-1 expression is significantly associated with gallbladder carcinomas. Furthermore the product of COX-2, PGH2 is converted by prostaglandin E2 synthase into PGE2, which in turn can stimulate cancer progression. Consequently inhibiting COX-2 may have benefit in the prevention and treatment of these types of cancer. PTGS2 is regulated by specific stimulatory events, suggesting that it is responsible for the prostanoid biosynthesis involved in inflammation and mitogenesis. It mediates the formation of prostaglandins from arachidonate and may have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|